Bose Arani 4
4 · Penumbra Inc · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Penumbra (PEN) Director Bose Arani Receives RSU Award
What Happened
Bose Arani, a director of Penumbra, Inc. (PEN), received a grant of 589 restricted stock units (RSUs) on February 13, 2026. The grant is reported at an acquisition price of $0.00 (i.e., an award/compensation grant rather than a purchase). The filing shows the shares are reported in connection with Bose Family Holdings II, LLC.
Key Details
- Transaction date: 2026-02-13; Filing date (Form 4): 2026-02-18.
- Transaction type/code: A — Award/Grant of RSUs. Price reported: $0.00.
- Shares granted: 589 RSUs. Shares owned after transaction: not specified in the filing.
- Vesting: RSUs vest 1/4 on each of Mar 31, Jun 30, Sep 30, and Dec 31, 2026, subject to continued service (footnote F1). A portion is subject to vesting (F2).
- Acceleration: Any unvested RSUs will fully vest upon the Closing of the announced merger with Boston Scientific, subject to continued service through the Closing (F1).
- Holding vehicle: Shares reported as held by Bose Family Holdings II, LLC (F3).
Context
RSU grants are common director compensation and do not require a cash outlay by the recipient. Because these are time-vested awards (with potential acceleration on the merger Closing), they indicate compensation alignment with future service and corporate events rather than an open-market purchase or sale. The filing does not disclose total post-transaction beneficial ownership, and no sale or purchase (open-market) occurred in this report.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-13+589→ 1,147 total
- 258,462(indirect: By LLC)
Common Stock
[F3]
Footnotes (3)
- [F1]Restricted stock units (RSUs) vest as to 1/4 on each of March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to Dr. Bose's continued service as director through such dates. Notwithstanding the foregoing, if the Closing (as defined in that certain Agreement and Plan of Merger, dated as of January 14, 2026, among the Issuer, Boston Scientific Corporation, a Delaware corporation, and Pinehurst Merger Sub, Inc., a Delaware corporation) occurs, any of the RSUs that remain unvested will fully vest on the Closing, subject to Dr. Bose's continued service as director through such date.
- [F2]A portion of these shares is subject to vesting.
- [F3]Shares are held by Bose Family Holdings II, LLC.